What's moving this stock lately
0 direct · 1 2nd-order · 0 thematicRanked by relevance and recency.
- #1Impact0.7%bearish2nd-orderBiogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience23d ago
A strengthened Biogen pipeline in Alzheimer's and adjacent areas poses potential long-run competitive pressure on Lilly's Kisunla and similar assets.
Also named: BIIB · SAGE
🎯 Market expectations
Estimate coverage Medium · 66/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$8.38 vs $6.01+39.43%
- Mar 2026$8.55 vs $7.06+21.1%
- Dec 2025$7.54 vs $6.99+7.87%
- Sep 2025$7.02 vs $6.02+16.61%
The takeaway
Recent results have exceeded consensus by an average of +21.3%, which may have raised expectations for the next report.
Analyst estimates, not our forecast · not investment advice
🏛️ Company factsSEC filings + FINRA official data
Annual revenue $65.2B · latest quarter up 47.7% YoY · profitable (FY net income $20.6B) · short activity within its normal range.
FY revenue
$65.2B
2025-12
Latest Q YoY
+47.7%
FY net income
$20.6B
Diluted EPS
$23
Short volume
47.3%
20d avg 47.1% · normal
🐋 5%+ ownership filings (last 180d)
The following investors reported beneficial ownership of more than 5% in recent SEC filings. "Activist" filers stated an intent to influence control of the company; "Passive" indicates the filer did not report such an intent.
- 2026-07-23passive (13G)LILLY ENDOWMENT INC
- 2026-05-01passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
🕰️ Price × news · analysis history
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
43 past analyses of this stock, each checked against what the price did afterwards · sign up to view
Start my free trialCurrent conviction
Crowding
Risk temperature
Tail risk
Triggers
Money flow
Insider signals
See every affected stock, second-order impact and risk factor. Try Pro free for 7 days — no credit card required.
Start my free trial